Carfilzomib-dexamethasone versus subcutaneous or intravenous bortezomib in relapsed or refractory multiple myeloma: secondary analysis of the phase 3 ENDEAVOR study.
Identifieur interne : 001041 ( Main/Exploration ); précédent : 001040; suivant : 001042Carfilzomib-dexamethasone versus subcutaneous or intravenous bortezomib in relapsed or refractory multiple myeloma: secondary analysis of the phase 3 ENDEAVOR study.
Auteurs : Hartmut Goldschmidt [Allemagne] ; Philippe Moreau [France] ; Heinz Ludwig [Autriche] ; Ruben Niesvizky [États-Unis] ; Wee-Joo Chng [Singapour] ; Douglas Joshua [Australie] ; Katja Weisel [Allemagne] ; Andrew Spencer [Australie] ; Robert Z. Orlowski [États-Unis] ; Shibao Feng [États-Unis] ; Karim S. Iskander [États-Unis] ; Meletios A. Dimopoulos [Grèce]Source :
- Leukemia & lymphoma [ 1029-2403 ] ; 2017.
Abstract
This is a secondary analysis of the phase 3 ENDEAVOR study comparing relapsed and/or refractory multiple myeloma (RRMM) patients receiving carfilzomib-dexamethasone (Kd) with those receiving subcutaneous (SC) bortezomib with dexamethasone (Vd) or intravenous (IV) Vd. Of Kd-treated patients, 356 Kd were pre-selected (by physician prior to randomization if to be randomized to Vd) for SC Vd (Kd [SC Vd]) and 108 for IV Vd (Kd [IV Vd], respectively. Of Vd-treated patients, 360 received SC Vd and 75 IV Vd. Kd (SC Vd) median PFS was not reached; SC Vd was 9.5 months. Median PFS for Kd (IV Vd) and IV Vd were 22.2 and 8.5 months, respectively. Median PFS was significantly longer and response rates were higher for Kd versus retreatment with bortezomib (SC or IV Vd) and in bortezomib naive patients. Overall, Kd was superior to Vd in RRMM regardless of route of bortezomib administration or prior bortezomib exposure.
DOI: 10.1080/10428194.2017.1376743
PubMed: 28937327
Affiliations:
- Allemagne, Australie, Autriche, France, Grèce, Singapour, États-Unis
- Californie, Texas, État de New York
Links toward previous steps (curation, corpus...)
- to stream PubMed, to step Corpus: 000584
- to stream PubMed, to step Curation: 000582
- to stream PubMed, to step Checkpoint: 000582
- to stream Ncbi, to step Merge: 004F05
- to stream Ncbi, to step Curation: 004F05
- to stream Ncbi, to step Checkpoint: 004F05
- to stream Main, to step Merge: 001036
- to stream Main, to step Curation: 001041
Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Carfilzomib-dexamethasone versus subcutaneous or intravenous bortezomib in relapsed or refractory multiple myeloma: secondary analysis of the phase 3 ENDEAVOR study.</title><author><name sortKey="Goldschmidt, Hartmut" sort="Goldschmidt, Hartmut" uniqKey="Goldschmidt H" first="Hartmut" last="Goldschmidt">Hartmut Goldschmidt</name><affiliation wicri:level="1"><nlm:affiliation>a Division of Multiple Myeloma , Universitatsklinikum Heidelberg , Heidelberg , Germany.</nlm:affiliation><country xml:lang="fr">Allemagne</country><wicri:regionArea>a Division of Multiple Myeloma , Universitatsklinikum Heidelberg , Heidelberg </wicri:regionArea><wicri:noRegion>Heidelberg </wicri:noRegion><wicri:noRegion>Heidelberg </wicri:noRegion><wicri:noRegion>Heidelberg </wicri:noRegion></affiliation></author><author><name sortKey="Moreau, Philippe" sort="Moreau, Philippe" uniqKey="Moreau P" first="Philippe" last="Moreau">Philippe Moreau</name><affiliation wicri:level="1"><nlm:affiliation>b Department of Hematology , University of Nantes , Nantes , France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>b Department of Hematology , University of Nantes , Nantes </wicri:regionArea><wicri:noRegion>Nantes </wicri:noRegion><wicri:noRegion>Nantes </wicri:noRegion></affiliation></author><author><name sortKey="Ludwig, Heinz" sort="Ludwig, Heinz" uniqKey="Ludwig H" first="Heinz" last="Ludwig">Heinz Ludwig</name><affiliation wicri:level="1"><nlm:affiliation>c Wilhelminen Cancer Research Institute , Wilhelminenspital , Vienna , Austria.</nlm:affiliation><country xml:lang="fr">Autriche</country><wicri:regionArea>c Wilhelminen Cancer Research Institute , Wilhelminenspital , Vienna </wicri:regionArea><wicri:noRegion>Vienna </wicri:noRegion></affiliation></author><author><name sortKey="Niesvizky, Ruben" sort="Niesvizky, Ruben" uniqKey="Niesvizky R" first="Ruben" last="Niesvizky">Ruben Niesvizky</name><affiliation wicri:level="2"><nlm:affiliation>d Multiple Myeloma Center, Weill Cornell Medical College , New York Presbyterian Hospital , New York , NY , USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>d Multiple Myeloma Center, Weill Cornell Medical College , New York Presbyterian Hospital , New York , NY </wicri:regionArea><placeName><region type="state">État de New York</region></placeName></affiliation></author><author><name sortKey="Chng, Wee Joo" sort="Chng, Wee Joo" uniqKey="Chng W" first="Wee-Joo" last="Chng">Wee-Joo Chng</name><affiliation wicri:level="1"><nlm:affiliation>e Department of Haematology-Oncology , National University Cancer Institute, National University Health System, Singapore and Cancer Science Institute of Singapore, National University of Singapore , Singapore.</nlm:affiliation><country xml:lang="fr">Singapour</country><wicri:regionArea>e Department of Haematology-Oncology , National University Cancer Institute, National University Health System, Singapore and Cancer Science Institute of Singapore, National University of Singapore </wicri:regionArea><wicri:noRegion>National University of Singapore </wicri:noRegion></affiliation></author><author><name sortKey="Joshua, Douglas" sort="Joshua, Douglas" uniqKey="Joshua D" first="Douglas" last="Joshua">Douglas Joshua</name><affiliation wicri:level="1"><nlm:affiliation>f Institute of Haematology , Royal Prince Alfred Hospital, the University of Sydney , Camperdown , New South Wales , Australia.</nlm:affiliation><country xml:lang="fr">Australie</country><wicri:regionArea>f Institute of Haematology , Royal Prince Alfred Hospital, the University of Sydney , Camperdown , New South Wales </wicri:regionArea><wicri:noRegion>New South Wales </wicri:noRegion></affiliation></author><author><name sortKey="Weisel, Katja" sort="Weisel, Katja" uniqKey="Weisel K" first="Katja" last="Weisel">Katja Weisel</name><affiliation wicri:level="1"><nlm:affiliation>g Department of Hematology, Oncology, Immunology, Rheumatology and Pulmonology , Universitatsklinikum Tubingen , Tubingen , Germany.</nlm:affiliation><country xml:lang="fr">Allemagne</country><wicri:regionArea>g Department of Hematology, Oncology, Immunology, Rheumatology and Pulmonology , Universitatsklinikum Tubingen , Tubingen </wicri:regionArea><wicri:noRegion>Tubingen </wicri:noRegion><wicri:noRegion>Tubingen </wicri:noRegion><wicri:noRegion>Tubingen </wicri:noRegion></affiliation></author><author><name sortKey="Spencer, Andrew" sort="Spencer, Andrew" uniqKey="Spencer A" first="Andrew" last="Spencer">Andrew Spencer</name><affiliation wicri:level="1"><nlm:affiliation>h Division of Blood Cancers , Alfred Health-Monash University , Melbourne , Victoria , Australia.</nlm:affiliation><country xml:lang="fr">Australie</country><wicri:regionArea>h Division of Blood Cancers , Alfred Health-Monash University , Melbourne , Victoria </wicri:regionArea><wicri:noRegion>Victoria </wicri:noRegion></affiliation></author><author><name sortKey="Orlowski, Robert Z" sort="Orlowski, Robert Z" uniqKey="Orlowski R" first="Robert Z" last="Orlowski">Robert Z. Orlowski</name><affiliation wicri:level="2"><nlm:affiliation>i Department of Lymphoma/Myeloma , The University of Texas MD Anderson Cancer Center, The University of Texas , Houston , TX , USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>i Department of Lymphoma/Myeloma , The University of Texas MD Anderson Cancer Center, The University of Texas , Houston , TX </wicri:regionArea><placeName><region type="state">Texas</region></placeName></affiliation></author><author><name sortKey="Feng, Shibao" sort="Feng, Shibao" uniqKey="Feng S" first="Shibao" last="Feng">Shibao Feng</name><affiliation wicri:level="2"><nlm:affiliation>j Amgen, Inc , Thousand Oaks , CA , USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>j Amgen, Inc , Thousand Oaks , CA </wicri:regionArea><placeName><region type="state">Californie</region></placeName></affiliation></author><author><name sortKey="Iskander, Karim S" sort="Iskander, Karim S" uniqKey="Iskander K" first="Karim S" last="Iskander">Karim S. Iskander</name><affiliation wicri:level="2"><nlm:affiliation>j Amgen, Inc , Thousand Oaks , CA , USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>j Amgen, Inc , Thousand Oaks , CA </wicri:regionArea><placeName><region type="state">Californie</region></placeName></affiliation></author><author><name sortKey="Dimopoulos, Meletios A" sort="Dimopoulos, Meletios A" uniqKey="Dimopoulos M" first="Meletios A" last="Dimopoulos">Meletios A. Dimopoulos</name><affiliation wicri:level="1"><nlm:affiliation>k Department of Clinical Therapeutics, School of Medicine , National and Kapodistrian University of Athens , Athens , Greece.</nlm:affiliation><country xml:lang="fr">Grèce</country><wicri:regionArea>k Department of Clinical Therapeutics, School of Medicine , National and Kapodistrian University of Athens , Athens </wicri:regionArea><wicri:noRegion>Athens </wicri:noRegion></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2017">2017</date><idno type="RBID">pubmed:28937327</idno><idno type="pmid">28937327</idno><idno type="doi">10.1080/10428194.2017.1376743</idno><idno type="wicri:Area/PubMed/Corpus">000584</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">000584</idno><idno type="wicri:Area/PubMed/Curation">000582</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">000582</idno><idno type="wicri:Area/PubMed/Checkpoint">000582</idno><idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">000582</idno><idno type="wicri:Area/Ncbi/Merge">004F05</idno><idno type="wicri:Area/Ncbi/Curation">004F05</idno><idno type="wicri:Area/Ncbi/Checkpoint">004F05</idno><idno type="wicri:Area/Main/Merge">001036</idno><idno type="wicri:Area/Main/Curation">001041</idno><idno type="wicri:Area/Main/Exploration">001041</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Carfilzomib-dexamethasone versus subcutaneous or intravenous bortezomib in relapsed or refractory multiple myeloma: secondary analysis of the phase 3 ENDEAVOR study.</title><author><name sortKey="Goldschmidt, Hartmut" sort="Goldschmidt, Hartmut" uniqKey="Goldschmidt H" first="Hartmut" last="Goldschmidt">Hartmut Goldschmidt</name><affiliation wicri:level="1"><nlm:affiliation>a Division of Multiple Myeloma , Universitatsklinikum Heidelberg , Heidelberg , Germany.</nlm:affiliation><country xml:lang="fr">Allemagne</country><wicri:regionArea>a Division of Multiple Myeloma , Universitatsklinikum Heidelberg , Heidelberg </wicri:regionArea><wicri:noRegion>Heidelberg </wicri:noRegion><wicri:noRegion>Heidelberg </wicri:noRegion><wicri:noRegion>Heidelberg </wicri:noRegion></affiliation></author><author><name sortKey="Moreau, Philippe" sort="Moreau, Philippe" uniqKey="Moreau P" first="Philippe" last="Moreau">Philippe Moreau</name><affiliation wicri:level="1"><nlm:affiliation>b Department of Hematology , University of Nantes , Nantes , France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>b Department of Hematology , University of Nantes , Nantes </wicri:regionArea><wicri:noRegion>Nantes </wicri:noRegion><wicri:noRegion>Nantes </wicri:noRegion></affiliation></author><author><name sortKey="Ludwig, Heinz" sort="Ludwig, Heinz" uniqKey="Ludwig H" first="Heinz" last="Ludwig">Heinz Ludwig</name><affiliation wicri:level="1"><nlm:affiliation>c Wilhelminen Cancer Research Institute , Wilhelminenspital , Vienna , Austria.</nlm:affiliation><country xml:lang="fr">Autriche</country><wicri:regionArea>c Wilhelminen Cancer Research Institute , Wilhelminenspital , Vienna </wicri:regionArea><wicri:noRegion>Vienna </wicri:noRegion></affiliation></author><author><name sortKey="Niesvizky, Ruben" sort="Niesvizky, Ruben" uniqKey="Niesvizky R" first="Ruben" last="Niesvizky">Ruben Niesvizky</name><affiliation wicri:level="2"><nlm:affiliation>d Multiple Myeloma Center, Weill Cornell Medical College , New York Presbyterian Hospital , New York , NY , USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>d Multiple Myeloma Center, Weill Cornell Medical College , New York Presbyterian Hospital , New York , NY </wicri:regionArea><placeName><region type="state">État de New York</region></placeName></affiliation></author><author><name sortKey="Chng, Wee Joo" sort="Chng, Wee Joo" uniqKey="Chng W" first="Wee-Joo" last="Chng">Wee-Joo Chng</name><affiliation wicri:level="1"><nlm:affiliation>e Department of Haematology-Oncology , National University Cancer Institute, National University Health System, Singapore and Cancer Science Institute of Singapore, National University of Singapore , Singapore.</nlm:affiliation><country xml:lang="fr">Singapour</country><wicri:regionArea>e Department of Haematology-Oncology , National University Cancer Institute, National University Health System, Singapore and Cancer Science Institute of Singapore, National University of Singapore </wicri:regionArea><wicri:noRegion>National University of Singapore </wicri:noRegion></affiliation></author><author><name sortKey="Joshua, Douglas" sort="Joshua, Douglas" uniqKey="Joshua D" first="Douglas" last="Joshua">Douglas Joshua</name><affiliation wicri:level="1"><nlm:affiliation>f Institute of Haematology , Royal Prince Alfred Hospital, the University of Sydney , Camperdown , New South Wales , Australia.</nlm:affiliation><country xml:lang="fr">Australie</country><wicri:regionArea>f Institute of Haematology , Royal Prince Alfred Hospital, the University of Sydney , Camperdown , New South Wales </wicri:regionArea><wicri:noRegion>New South Wales </wicri:noRegion></affiliation></author><author><name sortKey="Weisel, Katja" sort="Weisel, Katja" uniqKey="Weisel K" first="Katja" last="Weisel">Katja Weisel</name><affiliation wicri:level="1"><nlm:affiliation>g Department of Hematology, Oncology, Immunology, Rheumatology and Pulmonology , Universitatsklinikum Tubingen , Tubingen , Germany.</nlm:affiliation><country xml:lang="fr">Allemagne</country><wicri:regionArea>g Department of Hematology, Oncology, Immunology, Rheumatology and Pulmonology , Universitatsklinikum Tubingen , Tubingen </wicri:regionArea><wicri:noRegion>Tubingen </wicri:noRegion><wicri:noRegion>Tubingen </wicri:noRegion><wicri:noRegion>Tubingen </wicri:noRegion></affiliation></author><author><name sortKey="Spencer, Andrew" sort="Spencer, Andrew" uniqKey="Spencer A" first="Andrew" last="Spencer">Andrew Spencer</name><affiliation wicri:level="1"><nlm:affiliation>h Division of Blood Cancers , Alfred Health-Monash University , Melbourne , Victoria , Australia.</nlm:affiliation><country xml:lang="fr">Australie</country><wicri:regionArea>h Division of Blood Cancers , Alfred Health-Monash University , Melbourne , Victoria </wicri:regionArea><wicri:noRegion>Victoria </wicri:noRegion></affiliation></author><author><name sortKey="Orlowski, Robert Z" sort="Orlowski, Robert Z" uniqKey="Orlowski R" first="Robert Z" last="Orlowski">Robert Z. Orlowski</name><affiliation wicri:level="2"><nlm:affiliation>i Department of Lymphoma/Myeloma , The University of Texas MD Anderson Cancer Center, The University of Texas , Houston , TX , USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>i Department of Lymphoma/Myeloma , The University of Texas MD Anderson Cancer Center, The University of Texas , Houston , TX </wicri:regionArea><placeName><region type="state">Texas</region></placeName></affiliation></author><author><name sortKey="Feng, Shibao" sort="Feng, Shibao" uniqKey="Feng S" first="Shibao" last="Feng">Shibao Feng</name><affiliation wicri:level="2"><nlm:affiliation>j Amgen, Inc , Thousand Oaks , CA , USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>j Amgen, Inc , Thousand Oaks , CA </wicri:regionArea><placeName><region type="state">Californie</region></placeName></affiliation></author><author><name sortKey="Iskander, Karim S" sort="Iskander, Karim S" uniqKey="Iskander K" first="Karim S" last="Iskander">Karim S. Iskander</name><affiliation wicri:level="2"><nlm:affiliation>j Amgen, Inc , Thousand Oaks , CA , USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>j Amgen, Inc , Thousand Oaks , CA </wicri:regionArea><placeName><region type="state">Californie</region></placeName></affiliation></author><author><name sortKey="Dimopoulos, Meletios A" sort="Dimopoulos, Meletios A" uniqKey="Dimopoulos M" first="Meletios A" last="Dimopoulos">Meletios A. Dimopoulos</name><affiliation wicri:level="1"><nlm:affiliation>k Department of Clinical Therapeutics, School of Medicine , National and Kapodistrian University of Athens , Athens , Greece.</nlm:affiliation><country xml:lang="fr">Grèce</country><wicri:regionArea>k Department of Clinical Therapeutics, School of Medicine , National and Kapodistrian University of Athens , Athens </wicri:regionArea><wicri:noRegion>Athens </wicri:noRegion></affiliation></author></analytic><series><title level="j">Leukemia & lymphoma</title><idno type="eISSN">1029-2403</idno><imprint><date when="2017" type="published">2017</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">This is a secondary analysis of the phase 3 ENDEAVOR study comparing relapsed and/or refractory multiple myeloma (RRMM) patients receiving carfilzomib-dexamethasone (Kd) with those receiving subcutaneous (SC) bortezomib with dexamethasone (Vd) or intravenous (IV) Vd. Of Kd-treated patients, 356 Kd were pre-selected (by physician prior to randomization if to be randomized to Vd) for SC Vd (Kd [SC Vd]) and 108 for IV Vd (Kd [IV Vd], respectively. Of Vd-treated patients, 360 received SC Vd and 75 IV Vd. Kd (SC Vd) median PFS was not reached; SC Vd was 9.5 months. Median PFS for Kd (IV Vd) and IV Vd were 22.2 and 8.5 months, respectively. Median PFS was significantly longer and response rates were higher for Kd versus retreatment with bortezomib (SC or IV Vd) and in bortezomib naive patients. Overall, Kd was superior to Vd in RRMM regardless of route of bortezomib administration or prior bortezomib exposure.</div></front></TEI><affiliations><list><country><li>Allemagne</li><li>Australie</li><li>Autriche</li><li>France</li><li>Grèce</li><li>Singapour</li><li>États-Unis</li></country><region><li>Californie</li><li>Texas</li><li>État de New York</li></region></list><tree><country name="Allemagne"><noRegion><name sortKey="Goldschmidt, Hartmut" sort="Goldschmidt, Hartmut" uniqKey="Goldschmidt H" first="Hartmut" last="Goldschmidt">Hartmut Goldschmidt</name></noRegion><name sortKey="Weisel, Katja" sort="Weisel, Katja" uniqKey="Weisel K" first="Katja" last="Weisel">Katja Weisel</name></country><country name="France"><noRegion><name sortKey="Moreau, Philippe" sort="Moreau, Philippe" uniqKey="Moreau P" first="Philippe" last="Moreau">Philippe Moreau</name></noRegion></country><country name="Autriche"><noRegion><name sortKey="Ludwig, Heinz" sort="Ludwig, Heinz" uniqKey="Ludwig H" first="Heinz" last="Ludwig">Heinz Ludwig</name></noRegion></country><country name="États-Unis"><region name="État de New York"><name sortKey="Niesvizky, Ruben" sort="Niesvizky, Ruben" uniqKey="Niesvizky R" first="Ruben" last="Niesvizky">Ruben Niesvizky</name></region><name sortKey="Feng, Shibao" sort="Feng, Shibao" uniqKey="Feng S" first="Shibao" last="Feng">Shibao Feng</name><name sortKey="Iskander, Karim S" sort="Iskander, Karim S" uniqKey="Iskander K" first="Karim S" last="Iskander">Karim S. Iskander</name><name sortKey="Orlowski, Robert Z" sort="Orlowski, Robert Z" uniqKey="Orlowski R" first="Robert Z" last="Orlowski">Robert Z. Orlowski</name></country><country name="Singapour"><noRegion><name sortKey="Chng, Wee Joo" sort="Chng, Wee Joo" uniqKey="Chng W" first="Wee-Joo" last="Chng">Wee-Joo Chng</name></noRegion></country><country name="Australie"><noRegion><name sortKey="Joshua, Douglas" sort="Joshua, Douglas" uniqKey="Joshua D" first="Douglas" last="Joshua">Douglas Joshua</name></noRegion><name sortKey="Spencer, Andrew" sort="Spencer, Andrew" uniqKey="Spencer A" first="Andrew" last="Spencer">Andrew Spencer</name></country><country name="Grèce"><noRegion><name sortKey="Dimopoulos, Meletios A" sort="Dimopoulos, Meletios A" uniqKey="Dimopoulos M" first="Meletios A" last="Dimopoulos">Meletios A. Dimopoulos</name></noRegion></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Asie/explor/AustralieFrV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001041 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 001041 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Asie
|area= AustralieFrV1
|flux= Main
|étape= Exploration
|type= RBID
|clé= pubmed:28937327
|texte= Carfilzomib-dexamethasone versus subcutaneous or intravenous bortezomib in relapsed or refractory multiple myeloma: secondary analysis of the phase 3 ENDEAVOR study.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/RBID.i -Sk "pubmed:28937327" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd \
| NlmPubMed2Wicri -a AustralieFrV1
| This area was generated with Dilib version V0.6.33. |  |